If your pediatrician hasn't mentioned weight-loss medications at a recent well-child visit, there's a reasonable chance they might at the next one — particularly if your child is in a higher weight category. The numbers tell the story: prescriptions of GLP-1 receptor agonist drugs for children and teens have surged dramatically over the past two years, following updated guidelines from the American Academy of Pediatrics.

Which Drugs Are We Talking About?

The medications involved are the same class that have dominated adult health headlines: GLP-1 receptor agonists. The most commonly prescribed include:

• Semaglutide (sold as Wegovy for weight management, Ozempic for diabetes)
• Liraglutide (sold as Saxenda for weight management, Victoza for diabetes)

These drugs work by mimicking a hormone that regulates appetite. In adults, they've produced significant weight loss results. In children, studies show they do improve blood sugar control and weight in kids with obesity or type 2 diabetes. But they're not without tradeoffs.

What the Research Shows — Benefits and Side Effects

A 2026 review published in a peer-reviewed medical journal found that GLP-1 drugs "significantly improved" blood sugar control and weight in obese children and those with type 2 diabetes. That's the benefit side of the ledger.

On the other side: gastrointestinal side effects — nausea, vomiting, diarrhea, and constipation — were significantly more common among children taking these medications compared to placebo. For some kids, these effects are manageable; for others, they're significant enough to affect school attendance and quality of life.

It's also worth noting that fewer than 10% of kids who meet the clinical criteria for medication are actually being prescribed it. This is not widespread or casual prescribing — it's a targeted clinical tool.

Questions Worth Asking Your Pediatrician

If this topic comes up at a well-child visit, here are the questions most worth raising:

• What is the specific clinical threshold for considering medication in my child's case?
• What lifestyle interventions have we not yet tried, and how long should we try them first?
• What are the expected side effects, and how do we monitor for them?
• Is there long-term safety data for this age group?
• What happens if we decide to stop the medication?

Parents in Colorado Springs have access to pediatric specialists at Children's Hospital Colorado at its COS facilities and through local practices affiliated with larger regional health systems. A referral to a pediatric endocrinologist or obesity medicine specialist may be appropriate if you want a second opinion.

What's Next

The conversation around GLP-1 drugs for children is evolving quickly. The AAP guidelines continue to be updated as more long-term data becomes available. The back-to-school season, when annual well-child visits are common, is the natural time to have this conversation with your pediatrician — on your terms, with your questions ready.